Stugezin

**Stugezin** is a drug belonging to the group of calcium channel blockers intended to treat symptoms of cerebrovascular insufficiency, chronic cerebrovascular accidents, post-cerebral recovery period, depression, and Alzheimer's disease. This drug was created and first released in 2014.

Pharmacological properties: among the main pharmacological properties are central and peripheral effects, inhibition of lysosomal processes, antiexudative, antihistamine, vasoconstrictor effects, and also improves sleep. The drug is used to reduce hypercholesterolemia and lower blood pressure in the periphery.

When taking **Stugezn**, a hypnotic effect may develop, even beyond its real area of ​​application; in this case, reduce the dose of the drug. Research and the effects of the drug suggest that it is not addictive.

Indications: cerebrovascular disease, Alzheimer's disease, various types of depression, cerebrovascular insufficiency, tinnitus. Contraindications: hypersensitivity. Not suitable for women who are breastfeeding. Effect on the body: Side effects: impaired consciousness, visual disturbances, eye pain, irritability, worsening mood, possible impaired coordination of movements, fatigue. It is also possible that allergic reactions, pain in the abdominal cavity, and increased or decreased urination may occur. No cases of overdose have been identified.